论文部分内容阅读
目的观察奥拉西坦治疗急性颅脑损伤的临床疗效。方法76例符合研究条件的急性颅脑损伤患者,随机分为奥拉西坦治疗组38例和常规治疗组38例进行对比研究。观察治疗期间不同时期GCS评分,治疗结束后及康复期GOS评分。结果奥拉西坦治疗组GCS评分在用药7d后开始明显优于对照组(P<0.05),在2周的治疗期结束后和4个月后随访进行GOS评分,治疗组明显优于对照组(P<0.05)。随访结束后评定病死率,治疗组死亡5例(10.4%),对照组死亡12例(25.0%),显示两组间差异有统计学意义(P<0.05)。结论早期应用奥拉西坦治疗急性颅脑损伤疗效好,不良反应小。能明显降低病死率,改善预后。
Objective To observe the clinical efficacy of oxiracetam in the treatment of acute craniocerebral injury. Methods A total of 76 patients with acute craniocerebral injury who met the study conditions were randomly divided into two groups: 38 patients in the oxiracetam group and 38 patients in the conventional therapy group. The GCS score, the GOS score at the end of treatment and the convalescence period were observed during the treatment period. Results The GCS score of oxiracetam treatment group was significantly better than that of control group (P <0.05) on the 7th day after treatment, GOS score was observed after 2 weeks of treatment and 4 months after treatment, the treatment group was significantly better than the control group (P <0.05). Mortality was assessed after follow-up, with 5 deaths (10.4%) in the treatment group and 12 (25.0%) deaths in the control group, indicating a statistically significant difference between the two groups (P <0.05). Conclusions The early application of oxiracetam in the treatment of acute craniocerebral injury has good curative effect and small adverse reaction. Can significantly reduce mortality and improve prognosis.